100 related articles for article (PubMed ID: 28668826)
1. Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
Winters B; Brown L; Coleman I; Nguyen H; Minas TZ; Kollath L; Vasioukhin V; Nelson P; Corey E; Üren A; Morrissey C
Anticancer Res; 2017 Jul; 37(7):3385-3396. PubMed ID: 28668826
[TBL] [Abstract][Full Text] [Related]
2. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
4. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
Rahim S; Beauchamp EM; Kong Y; Brown ML; Toretsky JA; Üren A
PLoS One; 2011 Apr; 6(4):e19343. PubMed ID: 21559405
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.
Morrissey C; Dowell A; Koreckij TD; Nguyen H; Lakely B; Fanslow WC; True LD; Corey E; Vessella RL
Prostate; 2010 Dec; 70(16):1799-808. PubMed ID: 20583134
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract][Full Text] [Related]
7. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract][Full Text] [Related]
8. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
9. LuCaP 35: a new model of prostate cancer progression to androgen independence.
Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
Ellis WJ; Vessella RL; Buhler KR; Bladou F; True LD; Bigler SA; Curtis D; Lange PH
Clin Cancer Res; 1996 Jun; 2(6):1039-48. PubMed ID: 9816265
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
Mohamed AA; Xavier CP; Sukumar G; Tan SH; Ravindranath L; Seraj N; Kumar V; Sreenath T; McLeod DG; Petrovics G; Rosner IL; Srivastava M; Strovel J; Malhotra SV; LaRonde NA; Dobi A; Dalgard CL; Srivastava S
Cancer Res; 2018 Jul; 78(13):3659-3671. PubMed ID: 29712692
[TBL] [Abstract][Full Text] [Related]
12. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
[TBL] [Abstract][Full Text] [Related]
13. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
[TBL] [Abstract][Full Text] [Related]
14. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
Stangelberger A; Schally AV; Letsch M; Szepeshazi K; Nagy A; Halmos G; Kanashiro CA; Corey E; Vessella R
Int J Cancer; 2006 Jan; 118(1):222-9. PubMed ID: 16003723
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.
Clegg N; Ferguson C; True LD; Arnold H; Moorman A; Quinn JE; Vessella RL; Nelson PS
Prostate; 2003 Apr; 55(1):55-64. PubMed ID: 12640661
[TBL] [Abstract][Full Text] [Related]
16. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
18. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
Wang X; Qiao Y; Asangani IA; Ateeq B; Poliakov A; Cieślik M; Pitchiaya S; Chakravarthi BVSK; Cao X; Jing X; Wang CX; Apel IJ; Wang R; Tien JC; Juckette KM; Yan W; Jiang H; Wang S; Varambally S; Chinnaiyan AM
Cancer Cell; 2017 Apr; 31(4):532-548.e7. PubMed ID: 28344039
[TBL] [Abstract][Full Text] [Related]
19. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
